Back to the main directory
EarningsReview / Equity
- Star7 - Publie son premier rapport sur le développement durable by MidCap Partners
- Macro, Valuation, Exposures, Sensitivities and Performance Sheets by BNP Paribas Exane
- 2Q23: no miracle at Gucci, other businesses lacklustre by BNP Paribas Exane
- Aker Biomarine (Buy, TP: NOK45.00) - Q2e adj. EBITDA below consensus by DnB Markets
- Seafood - Fat Trout Weekly by DnB Markets
- Weekly news, topics & discussion by DnB Markets
- The weekly navigator by DnB Markets
- Not so transitory by BNP Paribas Exane
- Blown up? Not quite yet by BNP Paribas Exane
- Stress Testing the Inelastic Bear Thesis by BNP Paribas Exane
- Sustainability Weekly 19 – 23 Juin 2023 by Oddo BHF
- Filtronic - Diversification drives growing pipeline by Edison Investment Research
- Molecure - OATD-01 gearing up for Phase II by Edison Investment Research
- Biotechs: ESG, a future booster for the sector? by Oddo BHF
- China Gas Holdings (384 HK) by HSBC
- Chr. Hansen (Buy, TP: DKK571.00) - Pricing to offset softer volumes by DnB Markets
- Novo Nordisk (Buy, TP: DKK1380.00) - Focus on obesity at ADA 2023 by DnB Markets
- Vitrolife (Buy, TP: SEK320.00) - Q2e largely in line with consensus by DnB Markets
- AB Foods (ABF LN) by HSBC
- What do investors say? by BNP Paribas Exane
- Aston Martin Opts for Lucid by BNP Paribas Exane
- Prices, volumes, arbitrage opportunities, and implications on company profits by BNP Paribas Exane
- MedinCell - Hausse du CA en 2022, 1ers revenus commerciaux attendus pour 2023 by MidCap Partners
- PROSUS: RDOS. 2023 (ANÁLISIS BANCO SABADELL) by Sabadell
- All-time-high adjusted EBITA margin in Q2''23? by BNP Paribas Exane